Older women who use statins may be at an increased risk for diabetes mellitus, according to the results of a study published online January 9, in the Archives of Internal Medicine.
Older women who use statins may be at an increased risk for diabetes mellitus (DM), according to the results of a study published online January 9 in the Archives of Internal Medicine.
The results of this study imply that statin use may increase risk of new-onset DM in postmenopausal women and that potency or individual statin may not play a role, according to lead study author Annie L. Culver, BPharm, Divisions of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, Mass., and colleagues.
The authors examined statin use among postmenopausal women participating in the Women's Health Initiative (WHI), which recruited 161,808 postmenopausal women aged 50 to 79 years at 40 US clinical centers between 1993 and 1998 with ongoing follow-up. The investigators used WHI data through 2005 for a total of 153,840 women who had not been diagnosed with DM and with no missing data at baseline.
A total of 7.04% of the patients reported taking a statin medication. Researchers found statin use at baseline was associated with an increased risk of DM (HR=1.71; 95% CI, 1.61–1.83), and the association remained consistent after adjusting for other potential confounders (HR=1.48; 95% CI, 1.38–1.59) and was observed for all types of statin medications.
“The consequences of statin-induced DM have not been specifically defined and deserve more attention,” the authors wrote. “Given the wide use of statins in the aging population, further studies among women, men, and diverse ethnicities will clarify DM risk and risk management to optimize therapy.”
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More